RU2019100887A - Композиции антитела и белка - Google Patents
Композиции антитела и белка Download PDFInfo
- Publication number
- RU2019100887A RU2019100887A RU2019100887A RU2019100887A RU2019100887A RU 2019100887 A RU2019100887 A RU 2019100887A RU 2019100887 A RU2019100887 A RU 2019100887A RU 2019100887 A RU2019100887 A RU 2019100887A RU 2019100887 A RU2019100887 A RU 2019100887A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- salt
- protein
- composition
- free
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (36)
1. Свободная от соли композиция белка или антитела, включающая:
a. гистидин;
b. неионный поверхностно-активный агент;
c. сахар или сахарный спирт, выбранный из маннита, декстрозы, глюкозы, трегалозы и сахарозы;
d. аргинин;
e. лизин;
f. глицин или аланин;
g. метионин; и
h. белок или антитело;
где указанная композиция белка или антитела имеет значение рН, которое колеблется от рН 4,0 до рН 6,0 и где указанная композиция белка существенно не содержит неорганической соли.
2. Свободная от соли композиция белка или антитела по п. 1, где указанная композиция имеет вязкость, которая колеблется от 1 до 8 мПа⋅с при 22°С.
3. Свободная от соли композиция белка или антитела по п. 1, где указанная композиция имеет осмоляльность, которая колеблется от 240 до 380 ммоль/кг.
4. Свободная от соли композиция белка или антитела по п. 1, где указанный неионный поверхностно-активный агент представляет собой полисорбат, выбранный из полисорбата 20 и полисорбата 80.
5. Свободная от соли композиция белка или антитела по п. 1, где указанный сахар представляет собой сахарозу.
6. Свободная от соли композиция белка или антитела по п. 1, включающая от 10 мМ до 50 мМ аргинина.
7. Свободная от соли композиция белка или антитела по п. 1, включающая от 5 мМ до 10 мМ метионина.
8. Свободная от соли композиция антитела к TFPI, включающая:
a. гистидин,
b. неионный поверхностно-активный агент,
c. сахар или сахарный спирт, выбранный из маннита, декстрозы, глюкозы, трегалозы и сахарозы,
d. аргинин,
e. лизин,
f. глицин или аланин,
g. метионин, и
h. антитело к TFPI;
где указанная композиция антитела к TFPI имеет значение рН от рН 4,0 до рН 6,0 и где указанная композиция антитела к TFPI существенно не содержит неорганической соли.
9. Свободная от соли композиция антитела к TFPI по п. 8, где указанная композиция имеет значение вязкости, которое колеблется от 1 до 8 мПа⋅с при 22°С.
10. Свободная от соли композиция антитела к TFPI по п. 8, где указанная композиция имеет осмоляльность, которая колеблется от 240 до 380 ммоль/кг.
11. Свободная от соли композиция антитела к TFPI по п. 8, где указанный неионный поверхностно-активный агент представляет собой полисорбат, выбранный из полисорбата 20 и полисорбата 80.
12. Свободная от соли композиция антитела к TFPI по п. 8, где указанный сахар представляет собой сахарозу.
13. Свободная от соли композиция антитела к TFPI по п. 8, где указанное антитело к TFPI представляет собой человеческое IgG2 моноклональное антитело.
14. Свободная от соли композиция антитела к TFPI по п. 8, где указанное человеческое IgG2 моноклональное антитело содержит легкую цепь, включающую аминокислотную последовательность SEQ ID NO: 1, и тяжелую цепь, включающую аминокислотную последовательность SEQ ID NO: 2.
15. Способ лечения расстройства у пациента, где указанный способ включает введение указанному пациенту терапевтически эффективного количества композиции белка или антитела, включающей гистидин, полисорбат 80 или полисорбат 20, сахарозу, аргинин, лизин, глицин, метионин и белок или антитело при значении рН от рН 4,0 до рН 6,0, где указанная композиция белка или антитела существенно не содержит неорганической соли.
16. Способ по п. 15, где указанная композиция белка или антитела вводится внутривенно, подкожно или внутримышечно.
17. Способ по п. 15, где указанный белок или антитело представляет собой человеческое моноклональное антитело к TFPI.
18. Способ по п. 17, где указанное человеческое моноклональное антитело содержит легкую цепь, включающую аминокислотную последовательность SEQ ID NO: 1, и тяжелую цепь, включающую аминокислотную последовательность SEQ ID NO: 2.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/601,598 | 2012-08-31 | ||
US13/601,598 US8613919B1 (en) | 2012-08-31 | 2012-08-31 | High concentration antibody and protein formulations |
US13/843,780 | 2013-03-15 | ||
US13/843,780 US9592297B2 (en) | 2012-08-31 | 2013-03-15 | Antibody and protein formulations |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2015111341A Division RU2678097C2 (ru) | 2012-08-31 | 2013-08-28 | Композиции антитела и белка |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2019100887A true RU2019100887A (ru) | 2019-03-22 |
RU2019100887A3 RU2019100887A3 (ru) | 2019-08-27 |
Family
ID=49162239
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2019100887A RU2019100887A (ru) | 2012-08-31 | 2013-08-28 | Композиции антитела и белка |
RU2015111341A RU2678097C2 (ru) | 2012-08-31 | 2013-08-28 | Композиции антитела и белка |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2015111341A RU2678097C2 (ru) | 2012-08-31 | 2013-08-28 | Композиции антитела и белка |
Country Status (26)
Country | Link |
---|---|
US (7) | US9592297B2 (ru) |
EP (3) | EP2890718A1 (ru) |
JP (3) | JP6462567B2 (ru) |
CN (2) | CN114392353A (ru) |
AR (2) | AR092388A1 (ru) |
AU (3) | AU2013308902B2 (ru) |
BR (1) | BR112015003838A2 (ru) |
CA (2) | CA2883095C (ru) |
CY (1) | CY1121989T1 (ru) |
DK (1) | DK3117837T3 (ru) |
ES (1) | ES2741575T3 (ru) |
HK (1) | HK1210794A1 (ru) |
HR (1) | HRP20191299T1 (ru) |
HU (1) | HUE045652T2 (ru) |
IL (6) | IL294567A (ru) |
LT (1) | LT3117837T (ru) |
MX (2) | MX369653B (ru) |
PL (1) | PL3117837T3 (ru) |
PT (1) | PT3117837T (ru) |
RS (1) | RS59221B1 (ru) |
RU (2) | RU2019100887A (ru) |
SG (2) | SG11201501116RA (ru) |
SI (1) | SI3117837T1 (ru) |
TW (4) | TW201825116A (ru) |
UY (1) | UY34995A (ru) |
WO (1) | WO2014036071A1 (ru) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE47150E1 (en) | 2010-03-01 | 2018-12-04 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI) |
HUE042706T2 (hu) * | 2011-04-01 | 2019-07-29 | Bayer Healthcare Llc | Monoklonális ellenanyagok szövetifaktorút-inhibitor (TFPI) ellen |
AT512589B1 (de) * | 2012-03-12 | 2014-06-15 | Zizala Lichtsysteme Gmbh | Lichtleitelement für einen Laser-Fahrzeugscheinwerfer sowie Fahrzeugscheinwerfer |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
WO2015038811A2 (en) | 2013-09-11 | 2015-03-19 | Arsia Therapeutics, Inc. | Liquid protein formulations containing ionic liquids |
US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
US9982061B2 (en) | 2014-10-01 | 2018-05-29 | Medimmune Limited | Antibodies to ticagrelor and methods of use |
JP6716577B2 (ja) | 2014-10-01 | 2020-07-01 | イーグル・バイオロジクス・インコーポレイテッドEagle Biologics, Inc. | 粘度低下物質を含有する、多糖および核酸の調合薬 |
KR102068915B1 (ko) | 2015-08-19 | 2020-01-22 | 화이자 인코포레이티드 | 조직 인자 경로 억제제 항체 및 그의 용도 |
CN107921109A (zh) | 2015-08-19 | 2018-04-17 | 阿斯利康(瑞典)有限公司 | 稳定的抗ifnar1配制品 |
AU2016329034B2 (en) * | 2015-09-22 | 2019-05-23 | Pfizer Inc. | Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method |
EP3443346B1 (en) * | 2016-04-13 | 2023-08-30 | Medimmune, LLC | Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents |
JOP20180125B1 (ar) | 2016-06-30 | 2022-09-15 | Celltrion Inc | صيغة صيدلانية سائلة ثابتة |
US10279048B2 (en) | 2016-07-13 | 2019-05-07 | Reform Biologics, Llc | Stabilizing excipients for therapeutic protein formulations |
CA3036965A1 (en) | 2016-09-16 | 2018-03-22 | Leukocare Ag | A method for stabilization of a biopharmaceutical drug product during processing |
GEP20237513B (en) * | 2016-12-23 | 2023-06-12 | Serum Institute Of India Pvt Ltd | Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof |
EP3618871A4 (en) | 2017-05-02 | 2021-01-06 | Merck Sharp & Dohme Corp. | ANTI-LAG3 ANTIBODIES ETCO-FORMULATIONS ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
JOP20200275A1 (ar) | 2018-05-10 | 2020-11-02 | Regeneron Pharma | صيغ تحتوي على بروتين اندماج لمستقبلvegf مرتفعة التركيز |
JP2021529800A (ja) * | 2018-07-05 | 2021-11-04 | バイエル アクチェンゲゼルシャフトBayer Aktiengesellschaft | 抗FXIa抗体のための新規な安定した高濃度製剤 |
KR102337683B1 (ko) * | 2018-09-21 | 2021-12-13 | 주식회사 녹십자 | 고효율 항-tfpi 항체 조성물 |
JP7467438B2 (ja) * | 2018-10-18 | 2024-04-15 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗rsv抗体の製剤及びその使用方法 |
CN111346225A (zh) * | 2018-12-21 | 2020-06-30 | 上海张江生物技术有限公司 | 含有蛋白质的药物制剂 |
CN114786717A (zh) * | 2019-11-13 | 2022-07-22 | 辉瑞公司 | 稳定的水性抗-tfpi抗体制剂 |
WO2024026388A1 (en) * | 2022-07-27 | 2024-02-01 | Viela Bio, Inc. | Formulations comprising an immunoglobulin-like transcript 7 (ilt7)-binding protein |
Family Cites Families (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1064396A (en) | 1975-02-18 | 1979-10-16 | Myer L. Coval | Fractional precipitation of gamma globulin with polyethylene glycol |
US4075193A (en) | 1976-11-26 | 1978-02-21 | Parke, Davis & Company | Process for producing intravenous immune globulin |
US4374763A (en) | 1979-09-17 | 1983-02-22 | Morishita Pharmaceutical Co., Ltd. | Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof |
US4499073A (en) | 1981-08-24 | 1985-02-12 | Cutter Laboratories, Inc. | Intravenously injectable immune serum globulin |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4597966A (en) | 1985-01-09 | 1986-07-01 | Ortho Diagnostic Systems, Inc. | Histidine stabilized immunoglobulin and method of preparation |
EP0303746B2 (en) | 1987-08-21 | 1998-12-02 | Mallinckrodt Group Inc. | Stabilization of growth promoting hormones |
US4877608A (en) | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
US4912861A (en) * | 1988-04-11 | 1990-04-03 | Huang Ing Chung | Removable pressure-adjustable shock-absorbing cushion device with an inflation pump for sports goods |
US5096885A (en) | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
EP0417193B1 (en) | 1988-05-27 | 1993-08-04 | Centocor, Inc. | Freeze-dried formulation for antibody products |
CA2049342A1 (en) | 1989-03-27 | 1990-09-28 | Sally Bolmer | Formulations for stabilizing of igm antibodies |
US5217954A (en) | 1990-04-04 | 1993-06-08 | Scios Nova Inc. | Formulations for stabilizing fibroblast growth factor |
JPH0565233A (ja) | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
US6165467A (en) | 1991-07-20 | 2000-12-26 | Yoshihide Hagiwara | Stabilized human monoclonal antibody preparation |
JP2966592B2 (ja) | 1991-07-20 | 1999-10-25 | 萩原 義秀 | 安定化されたヒトモノクローナル抗体製剤 |
GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
US5849700A (en) | 1991-12-20 | 1998-12-15 | Novo Nordisk A/S | Pharmaceutical formulation |
ES2153418T3 (es) | 1993-02-23 | 2001-03-01 | Genentech Inc | Estabilizacion de polipeptidos tratados con solventes organicos por medio de excipientes. |
DE4344824C1 (de) | 1993-12-28 | 1995-08-31 | Immuno Ag | Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung |
US5580856A (en) | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
GB9418092D0 (en) | 1994-09-08 | 1994-10-26 | Red Cross Found Cent Lab Blood | Organic compounds |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
ES2435462T3 (es) | 1995-07-27 | 2013-12-19 | Genentech, Inc. | Formulación de proteína liofilizada isotónica estable |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6686191B1 (en) | 1995-09-22 | 2004-02-03 | Bayer Healthcare Llc | Preparation of virally inactivated intravenously injectable immune serum globulin |
SK101398A3 (en) | 1996-01-25 | 1998-12-02 | Schering Ag | Improved concentrated injection and infusion solutions for intravenous administration |
US5770700A (en) | 1996-01-25 | 1998-06-23 | Genetics Institute, Inc. | Liquid factor IX formulations |
KR100236393B1 (ko) | 1996-02-02 | 1999-12-15 | 나까니시 히로유끼 | 사람성장호르몬을 함유하는 의약제제 |
TWI240627B (en) | 1996-04-26 | 2005-10-01 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
GB9610992D0 (en) | 1996-05-24 | 1996-07-31 | Glaxo Group Ltd | Concentrated antibody preparation |
EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
CA2302708A1 (en) | 1997-08-21 | 1999-03-04 | Siemens Aktiengesellschaft | Method for transmitting user data that can be allocated to different applications |
GB9820525D0 (en) | 1998-09-21 | 1998-11-11 | Allergy Therapeutics Ltd | Formulation |
JP2000247903A (ja) | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
BR0014486A (pt) | 1999-10-04 | 2002-09-17 | Chiron Corp | Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado |
WO2001064241A1 (fr) | 2000-02-29 | 2001-09-07 | Chugai Seiyaku Kabushiki Kaisha | Preparations stabilisees a long terme |
DE60128793T2 (de) | 2000-04-07 | 2008-02-07 | Signal Coordinating Therapy Inc. | Verfahren und Zusammensetzung zur Behandlung von Neoplasmen |
EP1336410A4 (en) | 2000-08-04 | 2005-10-12 | Chugai Pharmaceutical Co Ltd | PROTEIN INJECTION PREPARATIONS |
US8632778B2 (en) | 2000-08-11 | 2014-01-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized anti-interleukin-6 antibody-containing preparations |
CN1204921C (zh) | 2000-09-01 | 2005-06-08 | 中外制药株式会社 | 长期稳定溶液制剂 |
PT1324776E (pt) | 2000-10-12 | 2009-12-23 | Genentech Inc | Formulações de proteína concentradas de viscosidade reduzida |
GB0113179D0 (en) | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
JP4317010B2 (ja) * | 2001-07-25 | 2009-08-19 | ピーディーエル バイオファーマ,インコーポレイティド | IgG抗体の安定な凍結乾燥医薬製剤 |
AU2002335815A1 (en) | 2001-10-16 | 2003-04-28 | Rxkinetix, Inc. | High-concentration protein formulations and method of manufacture |
CN1292655C (zh) | 2001-11-08 | 2007-01-03 | 蛋白质设计实验室股份有限公司 | IgG抗体稳定的液态药物制剂 |
US20030138416A1 (en) | 2001-12-03 | 2003-07-24 | Jesper Lau | Use of glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes |
AU2002351353A1 (en) | 2001-12-19 | 2003-09-02 | Genentech, Inc. | Stabilizing polypeptides which have been exposed to urea |
DK1475101T3 (da) | 2002-02-14 | 2011-01-10 | Chugai Pharmaceutical Co Ltd | Antistof-holdige farmaceutiske opløsninger |
JP4583762B2 (ja) | 2002-02-27 | 2010-11-17 | イミュネックス・コーポレーション | ポリペプチド製剤 |
AU2005254062B2 (en) | 2002-04-11 | 2011-02-17 | Medimmune, Llc | High pressure spray-dry of bioactive materials |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
US20040022792A1 (en) | 2002-06-17 | 2004-02-05 | Ralph Klinke | Method of stabilizing proteins at low pH |
NZ537687A (en) | 2002-06-21 | 2008-04-30 | Biogen Idec Inc | Buffered formulations for concentrating antibodies and methods of use thereof |
WO2004007520A2 (en) | 2002-07-12 | 2004-01-22 | Medarex, Inc. | Methods and compositions for preventing oxidative degradation of proteins |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
JP4584713B2 (ja) | 2002-10-08 | 2010-11-24 | ライナット ニューロサイエンス コーポレイション | 神経成長因子アンタゴニストを投与することによって術後疼痛を処置するための方法および神経成長因子アンタゴニストを含有する組成物 |
AU2003293543A1 (en) | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
DK1575517T3 (da) | 2002-12-24 | 2012-05-14 | Rinat Neuroscience Corp | Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme |
US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
ZA200507757B (en) | 2003-04-04 | 2007-01-31 | Genentech Inc | High concentration antibody and protein formulations |
NZ599196A (en) | 2003-07-15 | 2014-01-31 | Amgen Inc | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
PL1698640T5 (pl) | 2003-10-01 | 2019-12-31 | Kyowa Hakko Kirin Co., Ltd. | Sposób stabilizacji przeciwciała i stabilizowany preparat przeciwciała w postaci roztworu |
EP1532983A1 (en) | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
EP1712240B1 (en) | 2003-12-25 | 2015-09-09 | Kyowa Hakko Kirin Co., Ltd. | Stable water-based medicinal preparation containing antibody |
US20060051347A1 (en) | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
AU2006207901A1 (en) | 2005-01-28 | 2006-08-03 | Wyeth | Stabilized liquid polypeptide formulations |
CA2600608A1 (en) | 2005-03-08 | 2006-09-14 | Pharmacia & Upjohn Company Llc | Composition comprising human igg2 antibody and chelating agent |
EP1858928A2 (en) | 2005-03-08 | 2007-11-28 | Pharmacia & Upjohn Company LLC | Anti-m-csf antibody compositions having reduced levels of endotoxin |
ES2407468T3 (es) * | 2005-04-18 | 2013-06-12 | Yeda Research And Development Company Limited | Formulaciones de anticuerpos anti-hepatitis B (HBV) estabilizadas |
WO2007002543A2 (en) * | 2005-06-23 | 2007-01-04 | Medimmune, Inc. | Antibody formulations having optimized aggregation and fragmentation profiles |
DK1899462T3 (da) | 2005-07-02 | 2011-06-06 | Arecor Ltd | Stabile vandige systemer omfattende proteiner |
NZ564843A (en) | 2005-08-03 | 2012-05-25 | Immunogen Inc | Immunoconjugate formulations comprising an immunoconjugate and an excipient in a buffered aqueous solution |
AU2006295340B2 (en) | 2005-08-05 | 2010-11-11 | Amgen Inc. | Stable aqueous protein or antibody pharmaceutical formulations and their preparation |
CN101360821A (zh) | 2005-11-21 | 2009-02-04 | 圣诺菲·帕斯图尔有限公司 | 重组病毒的稳定制剂 |
WO2007074880A1 (ja) | 2005-12-28 | 2007-07-05 | Chugai Seiyaku Kabushiki Kaisha | 抗体含有安定化製剤 |
CA2638811A1 (en) | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
DE102006005094A1 (de) | 2006-02-04 | 2007-08-09 | Degussa Gmbh | Titandioxid und Polycarboxylatether enthaltende Dispersion |
WO2007147001A2 (en) | 2006-06-14 | 2007-12-21 | Imclone Systems Incorporated | Lyophilized formulations of anti-egfr antibodies |
DK2426150T3 (en) | 2006-06-30 | 2018-01-22 | Novo Nordisk As | ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF |
CN101522219A (zh) | 2006-10-12 | 2009-09-02 | 惠氏公司 | 改变抗体溶液中离子强度以减少乳光/聚集物 |
RU2009126420A (ru) * | 2006-12-11 | 2011-01-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Парентеральная лекарственная форма антитела к абета |
EP2703007A1 (en) | 2007-03-30 | 2014-03-05 | MedImmune, LLC | Antibodies with decreased deamidation profiles |
GB0707938D0 (en) | 2007-04-25 | 2007-05-30 | Univ Strathclyde | Precipitation stabilising compositions |
AU2008266051B2 (en) | 2007-06-14 | 2014-07-31 | Biogen Ma Inc. | Antibody formulations |
AU2008269086B2 (en) * | 2007-06-25 | 2014-06-12 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
UA107557C2 (xx) | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
WO2009070642A1 (en) | 2007-11-28 | 2009-06-04 | Medimmune, Llc | Protein formulation |
RU2563343C2 (ru) | 2007-12-14 | 2015-09-20 | Ново Нордиск А/С | Антитела к человеческому nkg2d и их применения |
CN105126099A (zh) * | 2007-12-21 | 2015-12-09 | 弗·哈夫曼-拉罗切有限公司 | 抗体制剂 |
RU2470628C2 (ru) | 2007-12-28 | 2012-12-27 | Биоинвент Интернешнл Аб | Состав |
BRPI0907532A2 (pt) | 2008-02-20 | 2015-07-28 | G2 Inflammation Pty Ltd | Anticorpos anti-c5ar humanizados |
WO2009120684A1 (en) | 2008-03-25 | 2009-10-01 | Medimmune, Llc | Antibody formulation |
EP2297203A1 (en) | 2008-06-30 | 2011-03-23 | Novo Nordisk A/S | Anti-human interleukin-20 antibodies |
UA112050C2 (uk) | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi) |
TR201802935T4 (tr) | 2008-09-19 | 2018-03-21 | Pfizer | Stabil sıvı antikor formülasyonu. |
JP2012510468A (ja) | 2008-11-28 | 2012-05-10 | アボット・ラボラトリーズ | 安定な抗体組成物およびこれを安定させるための方法 |
EP2196476A1 (en) | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
DK2379600T4 (da) | 2008-12-22 | 2021-01-04 | Novo Nordisk As | Antistoffer mod tissue factor pathway inhibitor |
AU2010221156A1 (en) | 2009-03-06 | 2011-09-22 | Genentech, Inc. | Antibody formulation |
JP2012530721A (ja) | 2009-06-18 | 2012-12-06 | ワイス・エルエルシー | 小モジュール免疫薬のための凍結乾燥製剤 |
EP2473527B1 (en) | 2009-09-03 | 2016-11-30 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
EP2332995A1 (en) * | 2009-12-10 | 2011-06-15 | Bayer Schering Pharma Aktiengesellschaft | Neutralizing prolactin receptor antibodies and their therapeutic use |
SI3409289T1 (sl) | 2010-02-26 | 2020-12-31 | Novo Nordisk A/S | Stabilni sestavki, ki vsebujejo protitelo |
USRE47150E1 (en) | 2010-03-01 | 2018-12-04 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI) |
WO2011108452A1 (ja) * | 2010-03-02 | 2011-09-09 | Jnc株式会社 | 還元反応器 |
EP2547355B1 (en) * | 2010-03-19 | 2017-01-11 | Baxalta GmbH | Tfpi inhibitors and methods of use |
BR112012030139A2 (pt) | 2010-05-28 | 2017-06-13 | Novo Nordisk As | composições estáveis de anticorpos de doses múltiplas compreendendo um anticorpo e um preservante |
JP5918246B2 (ja) * | 2010-10-06 | 2016-05-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 抗インターロイキン−4受容体(il−4r)抗体を含有する安定化製剤 |
HUE042706T2 (hu) | 2011-04-01 | 2019-07-29 | Bayer Healthcare Llc | Monoklonális ellenanyagok szövetifaktorút-inhibitor (TFPI) ellen |
US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
US8613919B1 (en) * | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
-
2013
- 2013-03-15 US US13/843,780 patent/US9592297B2/en active Active
- 2013-08-28 AU AU2013308902A patent/AU2013308902B2/en not_active Ceased
- 2013-08-28 US US14/421,607 patent/US20150209431A1/en not_active Abandoned
- 2013-08-28 SG SG11201501116RA patent/SG11201501116RA/en unknown
- 2013-08-28 JP JP2015529977A patent/JP6462567B2/ja active Active
- 2013-08-28 HU HUE16180643A patent/HUE045652T2/hu unknown
- 2013-08-28 SI SI201331538T patent/SI3117837T1/sl unknown
- 2013-08-28 CA CA2883095A patent/CA2883095C/en active Active
- 2013-08-28 LT LTEP16180643.5T patent/LT3117837T/lt unknown
- 2013-08-28 IL IL294567A patent/IL294567A/en unknown
- 2013-08-28 ES ES16180643T patent/ES2741575T3/es active Active
- 2013-08-28 RU RU2019100887A patent/RU2019100887A/ru not_active Application Discontinuation
- 2013-08-28 SG SG10201708215YA patent/SG10201708215YA/en unknown
- 2013-08-28 RU RU2015111341A patent/RU2678097C2/ru not_active IP Right Cessation
- 2013-08-28 CA CA3129277A patent/CA3129277A1/en active Pending
- 2013-08-28 EP EP13760179.5A patent/EP2890718A1/en not_active Withdrawn
- 2013-08-28 CN CN202111330122.3A patent/CN114392353A/zh active Pending
- 2013-08-28 PT PT16180643T patent/PT3117837T/pt unknown
- 2013-08-28 PL PL16180643T patent/PL3117837T3/pl unknown
- 2013-08-28 CN CN201380051319.0A patent/CN104684933B/zh active Active
- 2013-08-28 EP EP19175217.9A patent/EP3590536A1/en not_active Ceased
- 2013-08-28 EP EP16180643.5A patent/EP3117837B1/en active Active
- 2013-08-28 IL IL286784A patent/IL286784B/en unknown
- 2013-08-28 WO PCT/US2013/056970 patent/WO2014036071A1/en active Application Filing
- 2013-08-28 BR BR112015003838A patent/BR112015003838A2/pt not_active Application Discontinuation
- 2013-08-28 MX MX2015002411A patent/MX369653B/es active IP Right Grant
- 2013-08-28 RS RSP20190976 patent/RS59221B1/sr unknown
- 2013-08-28 DK DK16180643.5T patent/DK3117837T3/da active
- 2013-08-29 AR ARP130103085A patent/AR092388A1/es unknown
- 2013-08-29 UY UY0001034995A patent/UY34995A/es not_active Application Discontinuation
- 2013-08-30 TW TW106131685A patent/TW201825116A/zh unknown
- 2013-08-30 TW TW102131326A patent/TW201414496A/zh unknown
- 2013-08-30 TW TW108113538A patent/TW201927338A/zh unknown
- 2013-08-30 AR ARP130103099A patent/AR092400A1/es unknown
- 2013-08-30 TW TW102131180A patent/TWI609697B/zh not_active IP Right Cessation
- 2013-12-16 US US14/107,658 patent/US20140105892A1/en not_active Abandoned
-
2014
- 2014-08-12 US US14/457,408 patent/US9849181B2/en active Active
-
2015
- 2015-02-11 IL IL237188A patent/IL237188A0/en unknown
- 2015-02-24 MX MX2019013670A patent/MX2019013670A/es unknown
- 2015-11-27 HK HK15111675.2A patent/HK1210794A1/xx unknown
-
2017
- 2017-08-16 US US15/679,053 patent/US20180055940A1/en not_active Abandoned
- 2017-10-18 US US15/787,610 patent/US20180028669A1/en not_active Abandoned
-
2018
- 2018-05-11 AU AU2018203320A patent/AU2018203320B2/en not_active Expired - Fee Related
- 2018-12-17 JP JP2018235273A patent/JP2019048886A/ja active Pending
-
2019
- 2019-04-07 IL IL265864A patent/IL265864B/en active IP Right Grant
- 2019-04-07 IL IL265865A patent/IL265865A/en unknown
- 2019-07-18 HR HRP20191299TT patent/HRP20191299T1/hr unknown
- 2019-08-16 CY CY20191100881T patent/CY1121989T1/el unknown
-
2020
- 2020-01-08 AU AU2020200134A patent/AU2020200134A1/en not_active Abandoned
- 2020-11-11 US US17/095,102 patent/US20230190637A9/en not_active Abandoned
- 2020-12-06 IL IL279237A patent/IL279237A/en unknown
-
2021
- 2021-01-13 JP JP2021003390A patent/JP2021059602A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2019100887A (ru) | Композиции антитела и белка | |
RU2015111319A (ru) | Препараты антитела к рецептору анти-пролактина | |
JP2016515515A5 (ru) | ||
PE20200513A1 (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso | |
RU2015123476A (ru) | Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения | |
RU2019138507A (ru) | Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1 | |
RU2012131099A (ru) | Препарат антитела | |
JP2019514998A5 (ru) | ||
AR089787A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-ang2 | |
UA107211C2 (uk) | Стабілізовані склади, які містять антитіла до рецептора інтерлейкіну 6 (il-6r) | |
RU2012125254A (ru) | Составы антитела | |
SI2331090T1 (en) | Stable liquid antibody formulation | |
US20140044727A1 (en) | Formulations with reduced viscosity | |
AR095496A1 (es) | Formulaciones de anticuerpos anti-receptor de prolactina | |
JP2020509031A5 (ru) | ||
RU2017107847A (ru) | Стабильный состав на основе антитела к il-4r-альфа | |
RU2016131667A (ru) | Состав препарата нейрегулина | |
JP2013543505A5 (ru) | ||
RU2019100221A (ru) | Составы на основе антитела к CD19 | |
RU2010131179A (ru) | Жидкая композиция, содержащая антитело высокой концентрации | |
US20140023655A1 (en) | Formulations with reduced viscosity | |
RU2017101667A (ru) | Фармацевтические композиции | |
JP2019512012A5 (ru) | ||
HRP20220011T1 (hr) | Nova stabilna formulacija za fxia protutijela | |
MX2022004146A (es) | Composición farmacéutica de vector de virus adenoasociado y métodos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20201216 |